In carcinoma in situ and advanced cancers, TIA1 staining was observed in both the cytoplasm and the nucleus, and cytoplasmic TIA1 immunoreactivity was higher in advanced cancers than in carcinoma in situ. The gene discussed is TIA1; the disease is cancer.